Authors
Latest:
Future Perspectives in the Treatment of Chronic Lymphocytic LeukemiaConcluding their discussion, Drs Advani, Parrondo, and Chanan-Khan conclude that second-generation BTK inhibitors are the preferred first-line treatment in patients with chronic lymphocytic leukemia due to better efficacy and lower cardiovascular risk, with emerging therapies promising even better outcomes.
Latest:
Reviewed in ONCOLOGY®: Gender Representation on Guideline PanelsThis issues Publisher's Note focuses on a manuscript regarding gender equity on oncology guideline panels.
Latest:
Twenty Years of Advancing Discoveries and Treatment of Mantle Cell LymphomaIn 2023, the Lymphoma Research Foundation hosted the Mantle Cell Lymphoma Scientific Consortium and Workshop to discuss treatment advancements in the field.
Latest:
Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical TrialsA multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.
Latest:
Clinical Pearls on Treating Patients with NRG1 FusionsTeresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, offer key takeaways and conclude their discussion by offering advice for clinicians treating patients with NRG1 fusion–positive malignancies.
Latest:
ctDNA May Replace Bone Marrow Exams in Multiple Myeloma, Expert SaysAn expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Latest:
Radiologic Assessment May Be Used Before First Line Therapy for mccRCCA review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
Latest:
Treatment Experience for a Patient With GVHDA patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.
Latest:
Caring for Patients With Serious Mental Illness: Guide for the Oncology ClinicianVeronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.
Latest:
Evolving Role of Autologous Stem Cell Transplantation for Light Chain Amyloidosis in the Modern EraMuhamed Baljevic, MD, considers the role of autologous stem cell transplantation for light chain amyloidosis in a peer perspective accompanying an article by Iuliana Vaxman, MD, and Angela Dispenzieri, MD.
Latest:
Clinical Scenario: AE Management for Bispecific Therapy in R/R MMFollowing the review of a case of a patient with relapsed/refractory multiple myeloma, the panel provides expert perspectives on adverse event management practices.
Latest:
‘Number of Unanswered Questions’ Remain About Role of Stereotactic Radiation in Metastatic Kidney CancerAn expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.
Latest:
Supportive Care and Managing Toxicities Related to ADCs in TNBCA panel of medical oncologists provides insights on managing toxicities in patients with triple-negative breast cancer who are receiving antibody-drug conjugates.
Latest:
R Tyler Hillman, MD, PhD, on Important Contributors Needed to Treat Ovarian Granulosa Cell TumorsAn expert emphasizes how a big team is needed to properly employ the different therapeutic modalities needed to treat patients with ovarian granulosa cell tumors.
Latest:
Sjögren Syndrome Induced by Immune Checkpoint Inhibitors in a Patient with Advanced Renal Cell CarcinomaThis clinical quandary details a Mexican man, aged 77 years, who presented to the oncology clinic with a sternal mass. Based on the results, the patient fulfilled the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for Sjögren syndrome, thus the diagnosis triggered by immune checkpoint inhibitors was definitively established.
Latest:
Immunotherapy Continues to Influence Perioperative Bladder Cancer ManagementAt the recent 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Jean Hoffman-Censits, MD, reviews advances in the use of systemic therapy to aid surgical management of bladder cancer.
Latest:
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell CarcinomaIn this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
Latest:
Patient Advocate Speaks to Value of Communicating Developments in Breast CancerProviders should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Latest:
CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple MyelomaPanelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.
Latest:
Valentina Boni, MD, PhD, on Breast Cancer Advances from 2022 ASCOValentina Boni, MD, PhD, spoke about numerous trials in the breast cancer space presented at 2022 ASCO.
Latest:
Jeffrey Graham, MD, Talks Immunotherapy Use in Frontline Non-Clear Cell RCCCancerNetwork® sat down with Jeffrey Graham, MD, FRCPC, to discuss the effectiveness of immune checkpoint inhibitors as frontline therapy for non–clear cell renal cell carcinoma
Latest:
Future Perspectives on MRD Testing in Colorectal CancerThe expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.
